comparemela.com

Latest Breaking News On - Iopharmaceutical - Page 14 : comparemela.com

First-in-class drug shows promise as a safe and effective treatment for cannabis use disorder

A first-in-class drug engineered to selectively inhibit the signaling pathway of the cannabinoid receptor shows promise as a safe and effective treatment for cannabis use disorder (CUD), a condition where a person is unable to control their cannabis use, even though it's causing problems in their lives.

United statesDistrict of columbiaMargaret meg haneyFrancesr levinVincenzo piazzaDaelis farmaMegan craigNeurocentre magendieColumbia substance use research centerDrug administrationCannabis research laboratory at columbia psychiatryColumbia university irving medical centerNational institute of drug abuseCannabis research laboratoryDepartment of psychiatry at columbiaDivision on substance use disorders at columbia

Disc Medicine Opco : Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress - Form 8-K

Disc Medicine, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic. | June 9, 2023

Christina tartagliaJohn quiselVerge scientific communicationsExchange commissionEuropean hematology associationDisc medicine incDisc presents positive initial dataErythropoietic protoporphyriaChief executive officerWill savageChief medical officerGlobal impressionX linked protoporphyriaPrivate securities litigation reform actQuarterly reportDisc medicine opco inc stock exchange

Abeona Therapeutics Shares Drop 7% After FDA Feedback for EB-101 BLA

By Chris Wack Abeona Therapeutics shares were down 7%, to $3.99, after the clinical-stage biopharmaceutical company said Friday that it received feedback for a biologics license application. | June 9, 2023

Chris wackIndiana universityDrug administrationDow jonesAbeona therapeutics inc stock exchangePress releaseIcense abeo us00289y2063

NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares

NAARDEN, The Netherlands and MIAMI, June 09, 2023 NewAmsterdam Pharma Company N.V. , a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of. | June 9, 2023

United statesNew yorkNoord hollandVan lanschot kempenHannah deresiewiczWilliam blair companyNeither the companyNewamsterdam pharma companynv nasdaqEquity syndicate prospectus departmentExchange commissionFrazier lifesciences acquisition corporationSyndicate departmentCantor fitzgerald coOrdinary sharesPost effective amendmentCantor fitzgerald

Phathom Pharmaceuticals Announces Closing of Underwriters Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

FLORHAM PARK, N.J., June 09, 2023 Phathom Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced. | June 9, 2023

United statesNew yorkNick benedettoEvercore groupEquity syndicate prospectus departmentNeedham companyPhathom pharmaceuticalsExchange commissionPhathom pharmaceuticals incCompany annual report on formEquity capital marketsAnnual reportPrivate securities litigation reform actNc stock exchangePress releaseAstrointestinal phat us71722w1071

vimarsana © 2020. All Rights Reserved.